EcoDrugPlus

Tyrosine Kinase With Immunoglobulin-Like And Egf-Like Domains 1

Ensembl ID : ENSDARG00000004105
Gene Symbol: TIE1
5 Cross references
207 Possible Orthologues:

Utrophin

Ensembl ID : ENSDARG00000100222
Gene Symbol: UTRN
5 Cross references
168 Possible Orthologues:

Utrophin-Like

Ensembl ID : ENSDARG00000110192
Gene Symbol: LOC103909931
5 Cross references
244 Possible Orthologues:

V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog

Ensembl ID : ENSDARG00000010844
Gene Symbol: KRAS
5 Cross references
208 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 1

Ensembl ID : ENSDARG00000099657
Gene Symbol: AKT1
76 Enzyme and pathways 3 Cross references
203 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2

Ensembl ID : ENSDARG00000011219
Gene Symbol: AKT2
71 Enzyme and pathways 5 Cross references
199 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2, Like

Ensembl ID : ENSDARG00000103612
Gene Symbol: AKT2L
5 Cross references
185 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 3a

Ensembl ID : ENSDARG00000104810
Gene Symbol: AKT3A
5 Cross references
203 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSDARG00000098696
Gene Symbol: RELA
55 Enzyme and pathways 5 Cross references
201 Possible Orthologues:

V-Src Avian Sarcoma (Schmidt-Ruppin A-2) Viral Oncogene Homolog

Ensembl ID : ENSDARG00000008107
Gene Symbol: SRC
93 Enzyme and pathways 5 Cross references
198 Possible Orthologues:

Vascular Endothelial Growth Factor Aa

Ensembl ID : ENSDARG00000103542
Gene Symbol: VEGFAA
11 Enzyme and pathways 5 Cross references
180 Possible Orthologues:

Vascular Endothelial Growth Factor Ab

Ensembl ID : ENSDARG00000034700
Gene Symbol: VEGFAB
9 Enzyme and pathways 5 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).